Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Trial Profile

Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2016

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPEDITION-2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Nov 2016 According to an Eli Lilly and Company media release, the company will work with investigators to appropriately conclude the open-label extension of this and other two studies (EXPEDITION and EXPEDITION3).
    • 22 Jul 2015 Results of pooled analyses of this and two other trials (EXPEDITION1 and EXPEDITION-EXT) were presented at the Alzheimer's Association International Conference 2015 (AAIC), as per an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top